Skip to main content
Log in
(current)
MIT Open Scholarship
DSpace@MIT
Search
Home
MIT Open Access Articles
MIT Open Access Articles
Antitumor Antibodies Can Drive Therapeutic T Cell Responses
This is not the latest version of this item. The latest version can be found
here
.
Antitumor Antibodies Can Drive Therapeutic T Cell Responses
Download
Name
nihms892691.pdf
Description
Accepted version
Show more
Size
621.08 KB
Format
Adobe PDF
Checksum
(MD5)
d527230abf728cac567a56d0c5d8d2a5
Show more
sword-2019-09-13T18:23:58.original.xml (130 B)
Original SWORD entry document
Show more
Author(s)
Wittrup, K Dane
Date Issued
2017
Journal
Trends in Cancer
Publisher
Elsevier BV
Version
Author's final manuscript
Abstract
© 2017 Elsevier Inc. The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated antigens (TAAs) is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence that anti-TAA mAbs are capable of profoundly synergizing with T cell-directed immunotherapies such as checkpoint blockade and adoptive cell therapy. Two key components account for this synergy: (i) a self-vaccinal effect mediated by dendritic cells (DCs); and (ii) an inflammatory repolarization of the tumor microenvironment. Efficient exploitation of these mechanisms has tremendous therapeutic potential.
Show more
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/134531
DOI of Published Version
10.1016/J.TRECAN.2017.07.001
